Taysha Gene Therapies, Inc.
TSHA
$6.86
$0.010.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -129.88M | -109.00M | -99.93M | -92.72M | -86.77M |
| Total Depreciation and Amortization | 1.16M | 1.15M | 1.15M | 1.16M | 1.20M |
| Total Amortization of Deferred Charges | 147.00K | 147.00K | 147.00K | -- | -- |
| Total Other Non-Cash Items | 22.09M | 19.98M | 14.86M | 20.25M | 19.44M |
| Change in Net Operating Assets | -5.47M | -5.37M | -900.00K | -10.81M | -17.32M |
| Cash from Operations | -111.95M | -93.09M | -84.68M | -82.13M | -83.45M |
| Capital Expenditure | -384.00K | -738.00K | -486.00K | -413.00K | -612.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.87M | 134.00K | 142.00K | 82.00K | 18.00K |
| Cash from Investing | -3.26M | -604.00K | -344.00K | -331.00K | -594.00K |
| Total Debt Issued | 49.85M | 49.85M | 49.85M | -- | -- |
| Total Debt Repaid | -40.61M | -40.61M | -40.61M | -- | -- |
| Issuance of Common Stock | 266.48M | 265.86M | 216.25M | 223.01M | 77.32M |
| Repurchase of Common Stock | -173.00K | -173.00K | -573.00K | -400.00K | -400.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -191.00K | -337.00K | -237.00K | -133.00K | -264.00K |
| Cash from Financing | 275.35M | 274.59M | 224.68M | 222.47M | 76.65M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 160.15M | 180.90M | 139.66M | 140.02M | -7.39M |